Mymetics Corp (MYMX)

[Work Harder]

Sanofi Hiv direct interest in gp41

http://www.news.sanofi.us/2017-09-20-Sanofi-and-NIH-researchers-develop-three-in-one-antibodies-as-a-potential-breakthrough-intervention-for-HIV-AIDS

lil gp41 here

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978417/

So trispecific is used in HVTN 702

https://webcache.googleusercontent.com/search?q=cache:ZsNKzbVAM2kJ:https://www.abbexa.com/news/tag/hiv+&cd=7&hl=en&ct=clnk&gl=us

Monkeys received an injection of the tri-specific antibody and another injection full of the HIV virus. All 24 monkeys used in the study didn’t contract an infection from HIV. After this extraordinary result, a clinical trial is expected to be conducted in 2018.
As Sanofi’s Gary Nabel told the BBC, “[The tri-specific antibodies] are more potent and have greater breadth than any single naturally occurring antibody that’s been discovered.”

& upcoming HVTN 703 704 & 705